Literature DB >> 15815885

Partial splenic embolization in myelodysplastic syndrome associated with immune thrombocytopenia.

Hakan Ozdogu1, Can Boga, Levent Oğuzkurt, Ebru Kizilkilic.   

Abstract

BACKGROUND: Currently, all treatments for patients with myelodysplastic syndrome (MDS) are still experimental. Supportive care, including treatment of infection and transfusion of blood and blood-related products, remains the most important aspect of therapy in these cases. This article discusses the results of partial splenic embolization in a patient who had MDS with refractory anemia.
METHODS: The patient was placed under observation and was given supportive treatment. In addition to MDS with refractory anemia, there were management difficulties related to severe thrombocytopenia after alloimmunization from multiple blood transfusions. Therefore it is thought that partial splenic embolization might be an alternative treatment for the management thrombocytopenia.
RESULTS: Although the patient did not live long because of the sepsis and ileus, hematologic response was obtained.
CONCLUSION: The observation during the treatment in this case suggests that partial splenic embolization may be a valid new alternative for treating thrombocytopenia due to alloimmunization.

Entities:  

Mesh:

Year:  2004        PMID: 15815885     DOI: 10.1007/s11239-005-0349-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

Review 1.  Leucocyte depletion of the blood supply - how will patients benefit?

Authors:  L M Williamson
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

2.  Refractory anaemia according to the FAB classification: a report on 69 cases.

Authors:  P Fenaux; M H Estienne; P Lepelley; M Zandecki; J L Lai; R Beuscart; J P Jouet; A Cosson; F Bauters
Journal:  Eur J Haematol       Date:  1988-04       Impact factor: 2.997

3.  Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing.

Authors:  R A Yankee; F C Grumet; G N Rogentine
Journal:  N Engl J Med       Date:  1969-11-27       Impact factor: 91.245

4.  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Authors: 
Journal:  N Engl J Med       Date:  1997-12-25       Impact factor: 91.245

5.  Cytokine generation in stored platelet concentrates.

Authors:  G Stack; E L Snyder
Journal:  Transfusion       Date:  1994-01       Impact factor: 3.157

6.  A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions.

Authors:  N M Heddle; L N Klama; L Griffith; R Roberts; G Shukla; J G Kelton
Journal:  Transfusion       Date:  1993-10       Impact factor: 3.157

7.  Partial splenic embolization in five children with hypersplenism: effects of reduced-volume embolization on efficacy and morbidity.

Authors:  R K Harned; H R Thompson; D A Kumpe; M R Narkewicz; R J Sokol
Journal:  Radiology       Date:  1998-12       Impact factor: 11.105

8.  Myelodysplastic syndrome is not merely "preleukemia".

Authors:  Maher Albitar; Taghi Manshouri; Yu Shen; Diane Liu; Miloslav Beran; Hagop M Kantarjian; Anna Rogers; Iman Jilani; Chung Wu Lin; Sherry Pierce; Emil J Freireich; Elihu H Estey
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 9.  Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment.

Authors:  P Noël; L A Solberg
Journal:  Crit Rev Oncol Hematol       Date:  1992       Impact factor: 6.312

10.  Human preleukemia.

Authors:  H P Koeffler; D W Golde
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.